Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
38.66
-0.30 (-0.78%)
At close: Nov 20, 2026, 4:00 PM EST
38.64
-0.02 (-0.04%)
After-hours: Nov 20, 2026, 7:53 PM EST
Roivant Sciences Revenue
Roivant Sciences had revenue of $35.12M in the quarter ending September 30, 2026, with 2,135.58% growth. This brings the company's total for the last twelve months to $41.08M, up 102.09% year-over-year. In the fiscal year ending March 31, 2026, Roivant Sciences had annual revenue of $8.26M, down -71.57%. That makes Roivant Sciences the 29,398th largest company in the world by revenue and 3,899th in the United States.
Revenue (ttm)
$41.08M
Revenue Growth
+102.09%
P/S Ratio
681.76
Revenue / Employee
$56,979
Employees
721
Market Cap
28.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.26M | -20.79M | -71.57% |
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | -28.57M | -46.62% |
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | 65.37M | 2,812.61% |
| Mar 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Exelixis | 2.50B |
| Insmed | 1.52B |
ROIV News
- 4 days ago - Roivant Sciences Transcript: Jefferies Global Healthcare Conference - Transcripts
- 5 days ago - Roivant Sciences price target raised to $48 from $46 at Guggenheim - TheFly
- 11 days ago - Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology - GlobeNewsWire
- 11 days ago - Roivant Sciences price target raised to $48 from $47 at H.C. Wainwright - TheFly
- 11 days ago - Roivant Sciences price target raised to $42 from $41 at BofA - TheFly
- 12 days ago - Roivant Sciences Earnings Call Transcript: Q2 2027 - Transcripts
- 12 days ago - Roivant Sciences Quarterly report: Q2 2027 - Filings
- 12 days ago - Roivant Sciences Slides: Q2 2027 - Filings